# **Coinfections in pregnancy in hepatitis B virus (HBV)** screen-positive women in England

Emily Dema<sup>1,2</sup>, Rebecca Sconza<sup>2</sup>, Helen Peters<sup>2</sup>, Kate Francis<sup>2</sup>, Laura Smeaton<sup>3</sup>, Claire Thorne<sup>2</sup>

<sup>1</sup>Institute for Global Health, University College London, London, UK; <sup>2</sup>UCL Great Ormond Street Institute of Child Health, London, UK; <sup>3</sup>NHS England, London, UK

## BACKGROUND

- People living with HBV infections have higher risk of coinfections, reflecting shared transmission routes and risk factors across infections.
- In pregnancy, coinfections require careful management to optimise maternal health as well as pregnancy and infant outcomes, given potential risk of vertical transmission.
- We aimed to describe the prevalence of coinfections among pregnant women with HBV infection in England as well as treatment received.



## **METHODS**

- The Integrated Screening Outcomes Surveillance Service (ISOSS) conducts comprehensive, population-based surveillance of pregnant women with syphilis, HIV and HBV in England on behalf of the NHS Infectious Diseases in Pregnancy Screening Programme.
- ISOSS collects data on demographics, pregnancy management, clinical information, including coinfection in pregnancy.
- Analyses included pregnancies in **HBV screen-positive** women booking for antenatal care in England from 1 April 2021 to 31 March 2022, reported to ISOSS by 31 December 2022.
- Analysis focused on coinfections with HIV, syphilis, hepatitis C virus (HCV), and hepatitis Delta virus (HDV).

## RESULTS

- Characteristics of all 1988 HBV screen-positive pregnancies are shown in the Table.
- Coinfections were reported in 38 of 1986 (1.9%, 95%) CI: 1.4%-2.6%) HBV screen-positive pregnancies with available coinfection data.
- Coinfection prevalences (based on pregnancies) are presented in Figure 1.
- Two women with coinfections had two pregnancies reported - miscarriage followed by live birth in both cases (HBV/HIV and HBV/syphilis coinfections).

#### **Table.** Demographics of all HBV screen-positive pregnancies

Higher infectivity	7.2% (144/1987)
New HBV diagnosis in pregnancy	20.3% (502/1988)
Higher infectivity among the newly diagnosed	10.2% (41/402)
Higher infectivity among previously diagnosed	6.5% (103/1585)
Median age at delivery, years	30.9 (IQR 29.8-37.0)
Antenatal care in London	37.0% (735/1988)
Born outside the UK	95.3% (1837/1927)
Africa	37.5% (722/1927)
Asia	25.8% (497/1927)
Eastern Europe	23.8% (459/1927)

#### Figure 2. Timing of HBV diagnosis and infectivity status among 36 first pregnancies with coinfections to HBV screen-positive women



- Timing of HBV diagnosis and HBV infectivity markers among those with coinfections are shown in Figure 2.
- Higher infectivity markers were reported for 14.3%



Restricting to 36 first pregnancies with coinfection, 28 (77.8%) women had a prior HBV diagnosis before conception.



Figure 1. Prevalence of HBV coinfections, *N*=1986

(4/28) and 25.0% (2/8) of women with prior and new HBV diagnoses, respectively, compared to 6.4% (1554) and 9.9% 39/393) of pregnancies in monoinfected HBV screen-positive women.

### Among those with HBV/HIV:

- All 16 had prior HIV diagnoses and conceived on antiretroviral therapy (ART); 2 were newly diagnosed with HBV.
- All received appropriate ART regimens for management of HIV/HBV coinfections in pregnancy according to BHIVA guidelines.

#### Among those with HBV/syphilis:

- 4 had a new syphilis diagnosis, 2 of whom had a new HBV diagnosis.
- All 4 with new syphilis diagnosis received appropriate treatment.
- Whilst few HBV screen-positive pregnancies in England are complicated by HIV, syphilis, HCV or HDV coinfections, this group has a greater proportion of women with higher infectivity markers than HBV mono-infected women, though reassuringly
- Of those women coinfected with HIV or syphilis, most were **receiving appropriate management and treatment** for ٠ those infections.
- ISOSS is uniquely able to monitor this population that requires careful clinical management across services. ٠

CONTACT

#### ACKNOWLEDGEMENTS

www.ucl.ac.uk/isoss emily.dema.19@ucl.ac. uk @ISOSS\_UCL

CONCLUSIONS

ISOSS is a part of the NHS Infectious Diseases in Pregnancy Screening Programme (previously part of Public Health England) and is commissioned by NHS England. Data analysed belong to the NHS Infectious Diseases in Pregnancy Screening (IDPS) programme, NHS England, and are submitted by NHS providers. We would like to thank the NHS providers who report to ISOSS and to the ISOSS core team. ISOSS collects patient data under legal permissions granted under Regulation 3 of The Health Service (Control of Patient Information) Regulations 2022

